Cutaneous Mastocytosis: Diagnosis and Treatment for the Physician of First Contact

Article Sidebar

PDF
Published: Dec 10, 2022
DOI: https://doi.org/10.47191/ijmscrs/v2-i12-20
Keywords:
..

Main Article Content

Cinthia Mariel Constantino Rivera
Universidad del Valle de México, Campus Reynosa. Reynosa, Tamaulipas, México.
Edit Cano Muñoz
Facultad de Estudios Superiores Zaragoza. Universidad Nacional Autónoma de México. México.
Daniela Quintero Baca
Facultad de Medicina de la Universidad Nacional Autónoma de México. México.
Carolina Hernández Lúa
Universidad de Guadalajara. Guadalajara, Jalisco, México.
Gerardo Arauz Peña
Facultad de Medicina de la Universidad Nacional Autónoma de México. México.

Abstract

Mastocytosis is one of eight subcategories of neoplasms. Classification of Myeloproliferative Tumors of Lymphoid Tissues and hematopoietics of 2008 of the World Health Organization; is a heterogeneous group of myeloproliferative diseases that distinguished by excessive proliferation of mast cells morphologically and immunophenotypically atypical, in addition to the accumulation of these cells in one or more organs or tissues, including the skin, bone marrow bone, liver, spleen, and lymph nodes

Article Details

How to Cite
Constantino Rivera, C. M. ., Muñoz, E. C. ., Quintero Baca, D. ., Hernández Lúa, C. ., & Arauz Peña, G. . (2022). Cutaneous Mastocytosis: Diagnosis and Treatment for the Physician of First Contact. International Journal of Medical Science and Clinical Research Studies, 2(12), 1474–1478. https://doi.org/10.47191/ijmscrs/v2-i12-20
Issue
Vol. 2 No. 12 (2022): Volume 02 Issue 12 December 2022
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Brockow K, Jofer C, Behrendt Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008; 63:226-232.

II. Takemoto C. Mast cells-friend or foe? J Pediatr Hematol Oncol 2010; 32:342-344.

III. Akin C. Clonality and molecular pathogenesis of mastocytosis. Acta Haematol 2005; 114:61-69.

IV. Conde-Fernandes I, Anjos-Texeira M, Freitas I, et al. Adult mastocytosis: a review of the Santo Antonio Hospital’s experience and an evaluation of World Health Organization criteria for the diagnosis of systemic disease. An Bras Dermatol 2014; 89:55-66.

V. Sanchez-Muñoz L, Teodosio C, Morgado JM, et al. Immunophenotypic characterization of bone marrow mast cells in mastocytosis and other mast cell disorders. Methods Cell Biol 2011; 103:333-359.

VI. Amorim Oliveira AC, Mihon CE, Silva M, Galzerano A. Systemic mastocytosis-a diagnostic challenge. Revista Brasileira de Hematologia e Hemoterapia 2014; 36:226-229.

VII. Valent P. Diagnostic evaluation and classification of mastocytosis. Immunol Allergy Clin North Am 2006; 26:515-534.

VIII. Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, et al. Hematology: basic principles and practice. 4th ed. Philadelphia: Elsevier, 2005;911-925.

IX. Valent P, Escribano L, Broesby-Olsen S, et al. Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. Allergy 2014; 69:1267-1274.

X. Valent P. Biology, classification and treatment of human mastocytosis. Wien Klin Wochenschr 1996; 108:385-397.

XI. Sperr WR, Escribano L, Jordan JH, et al. Morphologic properties of neoplastic mas cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res 2001; 25:529-536.

XII. Valent P, Akin C, Sperr WR, et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 2003; 27:635-641.

XIII. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37:435-453.

XIV. Bonadonna P, Perbellini O, Passalacqa G, et al. Clonal mast cell disorders in patients with systemic reactions to hymenoptera stings and increased serum tryptase level. J Allergy Clin Immunol 2009; 123:680-686.

XV. Frieri M, Quershi M. Pediatric mastocytosis: A review of the literature. Pediatr Allergy Immunol Pulmonol 2013; 26:175-180.

XVI. Fried AJ, Akin C. Primary mast cell disorders in children. Curr Allergy Asthma Rep 2013; 13:693.

XVII. Akoglu G, Erkin G, Cakir B, Boztepe G, et al. Cutaneous mastocytosis: dermographic aspects and clinical features of 55 patients. J Eur Acad Dermatol Venereol 2006; 20:969-973.

XVIII. van Doormaal JJ, Arends S, Brunekreeft KL, et al. Prevalence of indolent systemic mastocytosis in a Dutcj region. JACI 2013; 131:1429-1431.

XIX. Miettnen M, Lasota J. KIT (CD117): A review on expresión in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunihistochem Mol Morphol 2005; 13:205-220.

XX. Quintas-Cardama A, Jain N, Verstovsek S. Advances and controversies in the diagnosis, pathogenesis and treatment of systemic mastocytosis. Cancer 2011; 117:5439-5449.

XXI. Kambe N, Longley BJ, Miyachi Y, et al. KIT masters mast in kids, too. J Invest Dermatol 2010; 130:648-650.

XXII. Bodemer C, Hermine O, Palmerini F, Yang Y, et al. Pediatric mastocytosis is a clinical disease associated with D816Vand other activating c-KIT mutations. J Invest Dermatol 2010; 130:804-815.

XXIII. Valent P, Spanbiochi E, Sperr WR, et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood momonuclear cells by recombinant human stem cell factor/kit ligand in long term culture. Blood 1992; 80:2237-2245.

XXIV. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell lines causing ligand-independent activation of c-kit product. J clin Invest 1993; 92:1736-1744.